BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 6, 2025
Breaking News: 100 days of uncertainty
See today's BioWorld Science
Home
» IGNX-001 prevents severe anaphylactic response to peanut challenge in mice
To read the full story,
subscribe
or
sign in
.
Immune
IGNX-001 prevents severe anaphylactic response to peanut challenge in mice
Feb. 27, 2024
Iggenix Inc. presented preclinical data for the novel allergen-specific antibody IGNX-001, being developed for the treatment of peanut allergy.
BioWorld Science
Conferences
Immune
